A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy. Materials and Methods: Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks. Results: 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0～6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5～19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%). Conclusion: The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer. (Cancer Res Treat. 2007; 39:6-9)
Abstract
Purpose: To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy. Materials and Methods: Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks. Results: 37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0～6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5～19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%). Conclusion: The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer. (Cancer Res Treat. 2007; 39:6-9)
참고문헌 (24)
- Bae JM, "Annual report of the Korea Central Cancer Registry Program 2000: based on registered data from 131 hospitals", 34, pp.77~83 (2002)
- "International Agency for Research on Cancer (IARC)" (2000)
- Ho D, "Ho D. Epidemiologic studies in gastric cancer. In" (1988), Churchill Livingstone
- Wilke HJ, "Current treatments and future perspectives in colorectal and gastric cancer", 14(2), pp.49~55 (2003)
- Waters JS, "Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial", 80, pp.269~272 (1999)
- Schiff PB, "Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979", pp.665~7
- Jordan MA, "Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death", 56, pp.816~825 (1996)
- Schiller JH, "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", 346, pp.92~98 (2002)
- Ajani JA, "Phase II study of Taxol in patients with advanced gastric carcinoma", 4, pp.269~274 (1998)
- Bokemeyer C, "A phase II trial of paclitaxel and weekly 24 h infusion of 5-fluorouracil", folinic acid in patients with advanced gastric cancer, 1997, pp.8, 396~399
- Kollmannsberger C, "A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer", 83, pp.458~462 (2000)
- Kim MK, "A multi-center, phase II clinical trial of Padexol (paclitaxel) and cisplatin for patients suffering with advanced gastric cancer", 37, pp.349~353 (2005)
- Vanhoefer U, "Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro", 31, pp.92~97 (1995)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors", 92, pp.205~216 (2000)
- Cascinu S, "Phase II study of paclitaxel in pretreated advanced gastric cancer", 9, pp.307~310 (1998)
- Ohtsu A, "An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer", 21, pp.416~419 (1998)
- Murad AM, "Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen", 22, pp.580~586 (1999)
- Kornek GV, "Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and", or erythropoietin in patients with advanced gastric cancer, 2002, pp.86, 1858~1863
- Ajani JA, "Irinotecan", cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma, 2002, pp.16(5), 16~18
- Suh SH, "with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (Modified FOLFOX-4) as a salvage therapy for patients with advanced gastric canc", 37, pp.279~283 (2005)
- Assersohn L, "Phase II study of irinotecan and 5-fluorouracil", leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, 2004, pp.15, 64~69
- Chun JH, "Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy", 34, pp.8~13 (2004)
- Stathopoulos GP, "Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study", 9, pp.89~92 (2002)
- Roth AD, "Docetaxel-based chemotherapy in the treatment of gastric cancer", 14(2), pp.41~44 (2003)